Expression of Cancer-associated Molecules in Malignant Mesothelioma

Overview

Journal Biomark Insights

Publisher Sage Publications

Date 2009 Aug 8

PMID 19662202

Citations 2

Authors

Ben Davidson

Affiliations

Soon will be listed here.

Abstract

Malignant mesothelioma (MM) is a malignant tumor derived from mesothelial cells, native cells of the body cavities. Exposure to asbestos is the most strongly established etiologic factor, predominantly for the most common disease form, pleural mesothelioma. The pathogenesis of MM involves the accumulation of extensive cytogenetic changes, as well as cancer-related phenotypic alterations that facilitate tumor cell survival, invasion and metastasis. This review presents current knowledge regarding the biological characteristics of this disease that are linked to the so-called hallmarks of cancer. In addition, data suggesting that the anatomic site (solid tumor vs. effusion) affects the expression of metastasis-associated and regulatory molecules in MM are presented. Finally, recent work in which high-throughput methodology has been applied to MM research is reviewed. The data obtained in the reviewed research may aid in defining new prognostic markers and therapeutic targets for this aggressive disease in the future.

Citing Articles

Multiplex Soluble Biomarker Analysis from Pleural Effusion.

Javadi J, Dobra K, Hjerpe A Biomolecules. 2020; 10(8).

PMID: 32731396 PMC: 7464384. DOI: 10.3390/biom10081113.

Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs) and caspases.

Cregan I, Dharmarajan A, Fox S Int J Oncol. 2012; 42(2):444-52.

PMID: 23229133 PMC: 3583754. DOI: 10.3892/ijo.2012.1715.

References

Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G . Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001; 193(4):468-75. DOI: 10.1002/path.824. View

Eltabbakh G, Piver M, Hempling R, Recio F, Intengen M . Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999; 70(1):6-12. DOI: 10.1002/(sici)1096-9098(199901)70:1<6::aid-jso2>3.0.co;2-x. View

Ruoslahti E . Integrins. J Clin Invest. 1991; 87(1):1-5. PMC: 294975. DOI: 10.1172/JCI114957. View

Hopkins-Donaldson S, Belyanskaya L, Simoes-Wust A, Sigrist B, Kurtz S, Zangemeister-Wittke U . p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia. 2006; 8(7):551-9. PMC: 1601933. DOI: 10.1593/neo.06148. View

Baldi A, Santini D, Vasaturo F, Santini M, Vicidomini G, Di Marino M . Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax. 2004; 59(5):428-33. PMC: 1746992. DOI: 10.1136/thx.2003.008912. View

Bedrossian C . Special stains, the old and the new: the impact of immunocytochemistry in effusion cytology. Diagn Cytopathol. 1998; 18(2):141-9. DOI: 10.1002/(sici)1097-0339(199802)18:2<141::aid-dc11>3.0.co;2-l. View

Dazzi H, Hasleton P, Thatcher N, Wilkes S, Swindell R, Chatterjee A . Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer. 1990; 61(6):924-6. PMC: 1971675. DOI: 10.1038/bjc.1990.207. View

Elenbaas B, Weinberg R . Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res. 2001; 264(1):169-84. DOI: 10.1006/excr.2000.5133. View

Lantuejoul S, Laverriere M, Sturm N, Moro D, Frey G, Brambilla C . NCAM (neural cell adhesion molecules) expression in malignant mesotheliomas. Hum Pathol. 2000; 31(4):415-21. DOI: 10.1053/hp.2000.6552. View

10.

Lopez-Rios F, Illei P, Rusch V, Ladanyi M . Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet. 2004; 364(9440):1157-66. DOI: 10.1016/S0140-6736(04)17102-X. View

11.

Galffy G, Mohammed K, Dowling P, Nasreen N, Ward M, Antony V . Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res. 1999; 59(2):367-71. View

12.

Edwards J, McLaren J, Jones J, Waller D, OByrne K . Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer. 2003; 88(10):1553-9. PMC: 2377107. DOI: 10.1038/sj.bjc.6600920. View

13.

OKane S, Pound R, Campbell A, Chaudhuri N, Lind M, Cawkwell L . Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol. 2006; 45(4):449-53. DOI: 10.1080/02841860500468927. View

14.

Davidson B, Zhang Z, Kleinberg L, Li M, Florenes V, Wang T . Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res. 2006; 12(20 Pt 1):5944-50. DOI: 10.1158/1078-0432.CCR-06-1059. View

15.

Miettinen M, Sarlomo-Rikala M . Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003; 27(2):150-8. DOI: 10.1097/00000478-200302000-00002. View

16.

Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K . Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006; 66(6):2970-9. DOI: 10.1158/0008-5472.CAN-05-3907. View

17.

Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F . The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother. 2004; 53(10):904-10. PMC: 11032983. DOI: 10.1007/s00262-004-0517-9. View

18.

Parker C, Neville E . Lung cancer * 8: Management of malignant mesothelioma. Thorax. 2003; 58(9):809-13. PMC: 1746789. DOI: 10.1136/thorax.58.9.809. View

19.

Hoang C, DCunha J, Kratzke M, Casmey C, Frizelle S, Maddaus M . Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest. 2004; 125(5):1843-52. DOI: 10.1378/chest.125.5.1843. View

20.

Hegmans J, Bard M, Hemmes A, Luider T, Kleijmeer M, Prins J . Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol. 2004; 164(5):1807-15. PMC: 1615654. DOI: 10.1016/S0002-9440(10)63739-X. View